<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1882">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136664</url>
  </required_header>
  <id_info>
    <org_study_id>PAT-CHINA-303</org_study_id>
    <secondary_id>CTR20212173</secondary_id>
    <nct_id>NCT05136664</nct_id>
  </id_info>
  <brief_title>Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects</brief_title>
  <official_title>A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Fresenius Medical Care Renal Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Fresenius Medical Care Renal Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, 2-part, single-blind, randomised, withdrawal, placebo-controlled&#xD;
      study, that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week&#xD;
      randomised placebo-controlled withdrawal phase (Part B) and a 2-week follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A, participants who meet all eligibility criteria will initiate patiromer at an oral&#xD;
      dose of 8.4 g (1 packet/day). The dose will be adjusted based on the serum potassium (sK+)&#xD;
      levels.&#xD;
&#xD;
      After the completion of part A, all the participants who meet the eligibility criteria for&#xD;
      Part B will be randomised to receive patiromer or placebo. Participants will start Part B&#xD;
      with the same dose of patiromer they were receiving at the end Part A. However, Patiromer&#xD;
      dose may be up- or down-titrated based on sK+ levels.&#xD;
&#xD;
      The primary objectives of the study are:&#xD;
&#xD;
      Part A - To evaluate the efficacy of patiromer for the treatment of hyperkalemia in Chinese&#xD;
      subjects.&#xD;
&#xD;
      Part B - To evaluate the effect of withdrawing patiromer on sK+ control. To determine if the&#xD;
      treatment with patiromer will result in continued use of renin-angiotensin-aldosterone system&#xD;
      inhibitor (RAASi) medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2-part, single-blind, randomised withdrawal, placebo-controlled (Part B), parallel group study that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part B).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Change from baseline in the serum potassium (sK+)</measure>
    <time_frame>Week 4</time_frame>
    <description>Measured in milliequivalents per litre (mEq/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change from Week 4 in sK+</measure>
    <time_frame>The earlier of: Week 8 or the date when RAASi therapy is first decreased or discontinued</time_frame>
    <description>Measured in mEq/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of participants having an sK+ level between 3.8 and less than 5.1 mEq/L at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of participants taking any RAASi medication at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects discontinuing/reducing RAASi medication due to hyperkalemia</measure>
    <time_frame>From Week 4 to 2 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperkalemia</condition>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Part A: Patiromer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: 4-week, single-arm patiromer treatment phase (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Patiromer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer Powder for Oral Suspension (Part A)</intervention_name>
    <description>Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.&#xD;
The content of each packet should be mixed with water, apple or cranberry juice before administration.</description>
    <arm_group_label>Part A: Patiromer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part B)</intervention_name>
    <description>Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.</description>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer Powder for Orals Suspension (Part B)</intervention_name>
    <description>Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.&#xD;
The content of each packet should be mixed with water, apple or cranberry juice before administration.</description>
    <arm_group_label>Part B: Patiromer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese subjects at least 18 years of age.&#xD;
&#xD;
          -  Chronic Kidney Disease (CKD) stage 3 and 4.&#xD;
&#xD;
          -  Serum potassium higher than 5.0 and lower than 6.5 mEq/L at Day 0/baseline.&#xD;
&#xD;
          -  Subjects on any stable dose of at least 1 RAASi medication for at least 28 days before&#xD;
             Day 0/baseline.&#xD;
&#xD;
          -  If on antihypertensive medication, have a stable dose for 28 days before Day&#xD;
             0/baseline.&#xD;
&#xD;
          -  Women of childbearing potential must agree to continue using contraception throughout&#xD;
             the study and for 4 weeks after study completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any level of hyperkalemia at Day 0/baseline that, in the opinion of the Investigator,&#xD;
             requires emergency intervention.&#xD;
&#xD;
          -  Type 1 diabetes or Type 2 diabetes mellitus with haemoglobin (Hb) A1c higher than&#xD;
             10.0% at Day 0/baseline.&#xD;
&#xD;
          -  History of acute renal insufficiency in the past 3 months prior to the beginning of&#xD;
             the study.&#xD;
&#xD;
          -  Diseases affecting the hearth muscle and heart's ability to pump blood around the body&#xD;
&#xD;
          -  Major surgery including thoracic and cardiac within 3 months prior to the beginning of&#xD;
             the study or anticipated need during study participation.&#xD;
&#xD;
          -  Heart or kidney transplant recipient or anticipated need for transplant during study&#xD;
             participation&#xD;
&#xD;
          -  Diagnosis or treatment of a malignancy in the past 2 years before Day 0/baseline.&#xD;
&#xD;
          -  Use of potassium supplements, bicarbonate or baking soda in the last 7 days prior to&#xD;
             Day 0/baseline.&#xD;
&#xD;
          -  Pregnant women or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Platon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vifor Pharma Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PAT-CHINA-303 Clinical Study Team</last_name>
    <phone>+41 588 518 000</phone>
    <email>pat-china-303.study@viforpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site 009</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 008</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 016</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 012</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 003</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 010</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 006</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 002</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 019</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 021</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 005</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 013</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>210031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 007</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 018</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 015</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 022</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 011</name>
      <address>
        <city>Yuncheng</city>
        <state>Shanxi</state>
        <zip>044099</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 004</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 014</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 023</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 020</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhengjiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 001</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhenjiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperkalemia</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

